Cosentyx（300 mg）是首个也是唯一获准用于治疗中至重度寻常型银屑病成人患者的白细胞介素-17A抑制剂。 在这项 IIIb 期研究中，Cosentyx 达到主要终点优 ...

Cosentyx 300 mg组和Cosentyx 150 mg组分别有89.5% 和82.3%的PsA患者实现了2年以上的无放射影像学进展（(mTSS0.5)）这一关键临床终点。 而且，接受剂量为300 mg的 ...

Cosentyx 300 mg组和Cosentyx 150 mg组分别有89.5% 和82.3%的PsA患者实现了2年以上的无放射影像学进展（(mTSS0.5)）这一关键临床终点。 而且，接受剂量为300 mg的 ...

Patient satisfaction with 300 mg autoinjector was high – reaching 100% – with no new safety signals observed over 52 weeks1 • Cosentyx is a proven medicine supported by sustained efficacy and safety ...

Patient satisfaction with 300 mg autoinjector was high – reaching 100% – with no new safety signals observed over 52 weeks 1 Cosentyx is a proven medicine supported by sustained efficacy and safety ...

For more information about the common dosages of Cosentyx, see this detailed article. liquid solution inside single-dose prefilled injection pens 150 mg/mL and 300 mg/2 mL liquid solution inside ...

Novartis reported that FUTURE 2 met its primary endpoint at week 24 as subcutaneous doses of Cosentyx (300 mg and 150 mg) led to improvements that sustained over one year of treatment in the ...

After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who were PASI ...

A randomized study found that secukinumab (Cosentyx) 300 mg resulted in rapid and significant improvements in symptoms of psoriatic arthritis (PsA) in biologic-naive patients, compared with placebo.

After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who were PASI 75 ...

The FDA approval was based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE, in which a higher proportion of patients given Cosentyx 300 mg either every two weeks ...